Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). (13th June 2019)

• Record Type: Journal Article
• Authors: Lal, Chitra; Strange, Charlie
• Is Part Of: Expert opinion on pharmacotherapy. Volume 20:Number 9(2019)
• Page Start: 1075
• Page End: 1085
• Publication Date: 2019-06-13
• Subjects: Chronic obstructive pulmonary disease -- fluticasone furoate -- vilanterol -- global initiative for obstructive lung disease -- exacerbations; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2019.1603292
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Inhaled corticosteroid/long-acting β-2 agonists (ICS/LABA) combination inhalers have been a lifeline for a generation of chronic obstructive pulmonary disease (COPD) and asthma patients. Fluticasone furoate and Vilanterol (FF/VI) as a once-daily ICS/LABA combination have an extensive clinical trial and real-world data to support its use in COPD patients. Areas covered : The authors provide pharmacological profiles of fluticasone furoate, vilanterol and the FF/VI fixed dose combination. Salient clinical trials evaluating efficacy and safety of the FF/VI combination, and studies demonstrating the impact on COPD exacerbation risk and mortality are also discussed. Expert opinion : ICS/LABA combinations provide bronchodilation and decrease the frequency of COPD exacerbations. Individualizing treatment of each COPD patient based on unique phenotypes will maximize chances of therapeutic responsiveness. Asthma-COPD overlap (ACO), patients with sputum and/or blood eosinophilia, patients with a brisk bronchodilator response, and patients with frequent exacerbations are more likely to show a therapeutic response to ICS than populations who have none of these features. FF/VI will likely remain a popular ICS/LBA combination to treat COPD, as a once-daily inhaled therapy delivered via the Ellipta device popular with COPD patients, with extensive clinical trial and real-world data to support its use.